 MALVERN, Pa., May 19, 2021 GLOBE NEWSWIRE -- TELA Bio, Inc. TELA, a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today launched the companys second post-market study, BRAVO II, to evaluate the clinical performance of OviTex Reinforced Tissue Matrices in the robotic repair of ventral hernias. The first patient was enrolled at St. Lukess Hospital in Overland Park, Kansas. 